Privacy policy
EEMA AI Section -
Built for Regulated Environments
PATENT PENDING
Ai for lab work
Built for Regulated Environments- Your bioprocess operations generate thousands of decisions daily. EEMA monitors every run, learns from every deviation, and proposes evidence-based rescue strategies, before regulators ever need to get involved. Available for acquisition or licensing
About
EEMA is an autonomous multi-agent AI digital twin for upstream bioprocess operations. Designed to run continuously, it maintains full regulatory traceability across every decision, meeting the human in the loop requirements of the EU AI Act 2026. Built on a persistent Memory Lattice knowledge graph, every parameter, risk flag, and hypothesis is stored with full metadata and audit trail.
Novelty
No existing system combines persistent evidence weighted knowledge graphs, autonomous literature validation, and regulatory ready traceability in a single architecture. Formally reviewed by Innovate UK and recognised for disruptive potential and valid market need.
Formally assessed by Innovate UK with a 70% application score. Disruptive potential recognised.
Request a technical demonstration
Contact today
EEMA is an autonomous, multi-agent AI digital twin for upstream bioprocess operations. It runs continuously, learns from every run, and provides evidence-based recommendations — with full regulatory traceability built into its core.
24/7
Continuous monitoring
100%
Decision traceability
70%
Innovate UK assessment score
EEMA watches every run, learns from every deviation, and proposes rescue strategies before problems escalate, while keeping your team fully in control of every decision.
With the EU AI Act full compliance deadline in August 2026, EEMA's human-in-the-loop model, automatic decision logging, and full audit trail meet the mandatory requirements for high-risk AI systems — by design, not by retrofit.
EEMA has been independently assessed by Innovate UK, the UK government's innovation agency. Three assessors reviewed the technology against criteria including technical approach, commercial impact, and scalability. The assessment confirmed disruptive potential and a valid market need — with currently limited competition.
EEMA is a working prototype ready for demonstration. We are seeking an established laboratory, biotech organisation, or pharmaceutical company with the infrastructure to bring it fully to market.
Payment options:
Acquisition with Royalties
Upfront acquisition payment plus a negotiated royalty for each sale.
Outright Code Acquisition could be possible.
Full transfer of intellectual property, source code, and technical documentation. One transaction. Complete ownership.